Atoltivimab + maftivimab + odesivimab

Essential medicine status

General description

INN	Atoltivimab + maftivimab + odesivimab
Medicine type	Biological agent
EML status history	First added in 2023 (TRS 1049) for Ebola virus disease
Wikipedia	Atoltivimab + maftivimab + odesivimab
DrugBank	Atoltivimab, Maftivimab, Odesivimab

Recommendations

Section Medicines for Ebola virus disease

- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

Ebola virus disease